Introduction {#sec1-1}
============

Traumatic spinal cord injury (SCI) results in the destruction of nervous tissue and a partial or complete loss of neurological functions. However, effective treatments are still lacking. The pathology of SCI can be divided into two distinct phases: the initial physical events that result in axonal damage and the later secondary injury processes that involve persistent inflammation, apoptosis, glutamate excitotoxicity, lipid peroxidation and free radical production (Oyinbo, 2011; Hayta and Elden, 2017).

Therefore, SCI can be considered to consist of primary and secondary injury mechanisms (Norenberg et al., 2004). The primary injury occurs seconds to minutes after the initial insult, while the secondary injury proceeds over a time course of minutes to months. It is thought that the poor outcome following SCI is mainly a result of the secondary damage (Oyinbo, 2011). Among the various mechanisms of secondary damage, inflammation plays a particularly critical role (Anwar et al., 2016). The inflammatory cytokines and chemokines released from spinal cord cells lead to the sequential activation and migration of microglia towards the lesion and the recruitment of circulating monocytes to the site of injury (Taoka and Okajima, 2000; Donnelly and Popovich, 2008). There is a consensus that inflammation has both beneficial and detrimental effects. In the first week after SCI, the destructive effects outweigh the beneficial effects, perhaps because lesion-derived inflammatory cytokines induce migrating peripheral blood monocytes into classically activated pro-inflammatory macrophages that persist for 1 month. In comparison, alternatively activated macrophages, which are anti-inflammatory, persist for a very short period of time (Kigerl et al., 2009; Kong and Gao, 2017). The classically activated macrophages produce high levels of inflammatory factors, such as interleukin (IL)-1β, IL-6 and inducible nitric oxide synthase, resulting in a local microenvironment that is not conducive to the survival of resident neurons, oligodendrocytes or transplanted cells (Garcia et al., 2016).

Over the past decade, cell transplantation has shown limited effectiveness (Nando Tewariem et al., 2009; Cusimano et al., 2012; Quertainmont et al., 2012; Guest et al., 2013; Kamei et al., 2013; Kolar et al., 2014; Muheremu et al., 2016). A hostile microenvironment and adaptive immune responses in the injured spinal cord might contribute to the low effectiveness of cell transplantation. It is reported that only a small number of transplanted cells exert beneficial effects because more than 90% of cells are cleared during the first few days after transplantation (Zhang et al., 2001; Paul et al., 2009; Van der bogt et al., 2009; Torres-Espin et al., 2014). In addition, many studies suggest that the beneficial effects obtained after cell transplantation are more likely the results of paracrine mechanisms rather than effective integration and differentiation of the transplanted cells within the host tissue (Himes et al., 2006; Rooney et al., 2009). Accordingly, an increasing number of studies have focused on the use of conditioned media from stem cells or differentiated cells for treating SCI. The new methods have shown therapeutic potential by providing neuroprotection and by promoting axonal regeneration and alleviating inflammation (Montoya et al., 2009; Cantinieaux et al., 2013; Guo et al., 2016; Cheng et al., 2017; Gu et al., 2017).

Endothelial progenitor cells (EPCs), mainly obtained from bone marrow or peripheral blood, secrete a variety of growth factors, such as hepatocyte growth factor, IL-8, platelet-derived growth factor, stromal cell-derived factor 1, vascular endothelial growth factor and brain-derived neurotrophic factor (Di Santo et al., 2009; Di Stefano et al., 2009; Zhao et al., 2016). Fujioka et al. (2012) and Kamei et al. (2012, 2013) reported that transplantation of human blood-derived CD133^+^ cells improves functional recovery after SCI. Our previous study showed that EPCs promote neural stem cell proliferation and differentiation *in vitro* (Du et al., 2016). Moreover, human peripheral blood-derived EPC-conditioned medium (EPC-CM) has been shown to be as effective as cell transplantation in promoting tissue revascularization and functional recovery in a rat model of chronic hind limb ischemia (Di Santo et al., 2009). Nevertheless, it is unknown whether EPC-CM promotes functional recovery after contusive SCI. In the present study, we investigated whether EPC-CM inhibits inflammation, promotes angiogenesis and provides neuroprotection.

Materials and Methods {#sec1-2}
=====================

Animals {#sec2-1}
-------

For primary culture of bone marrow EPCs, 24 4-week-old female Sprague-Dawley rats, weighing 80--100 g, were used. For primary culture of bone marrow-derived macrophages, 12 C57/BL6 mice, weighing 14--20 g, were used. For culture of spinal neurons, six 24-hour-old Sprague-Dawley pups were used. For *in vivo* experiments, 30 healthy adult female Sprague-Dawley rats, weighing 200--250 g, were used. All animals were specific-pathogen-free and provided by the Experimental Animal Center of Anhui Medical University of China (license No. SCXK (Wan) 2011-002). The experimental procedure followed the United States National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 1985), and was in accordance with the *Consensus Author Guidelines on Animal Ethics and Welfare* produced by the International Association of Veterinary Editors. The study protocol was approved by the Animal Ethics Committee of Anhui Medical University of China (No. LLSC 20150344).

*In vitro* experiments {#sec2-2}
----------------------

### Primary culture of EPCs and EPC-CM collection {#sec3-1}

EPCs were cultured as described in a previous report with slight modification (Brunt et al., 2007). Bone marrow mononuclear cells were isolated from the bone marrow of 4-week-old female Sprague-Dawley rats by density gradient centrifugation, and these cells were incubated on culture dishes coated with fibronectin in endothelial cell growth medium (Lonza, MD, USA). To produce EPC-CM, EPCs were cultured for 48 hours under hypoxic conditions (1.5% O~2~, 5% CO~2~, 93.5% N~2~) in serum and growth factor-free endothelial cell basal medium (Lonza, MD, USA). The conditioned medium was collected and centrifuged at 4000 ×*g* for 30 minutes at 4°C using 3-kDa MW cut-off filter units (Millipore, Bedford, MA, USA), and then sterilized through a 0.4-µm filter. This concentrated medium (*i.e*., the EPC-CM) was stored at −80°C until use. Growth factor and serum-free endothelial cell basal medium served as control medium (Con-M).

### Primary culture of mouse bone marrow-derived macrophages and assessment of the effect of EPC-CM on inflammation {#sec3-2}

Mouse bone marrow-derived macrophages were prepared as previously described (Ying et al., 2013). Briefly, bone marrow was harvested from C57/BL6 mouse femoral and tibial shafts. Cells were cultured for 7 days in Dulbecco's modified Eagle's medium/high glucose (DMEM/HG; Gibco, Grand Island, USA) supplemented with 10% fetal bovine serum (FBS), macrophage colony stimulating factor (10 ng/mL, PeproTech, NJ, USA) and 1% penicillin/streptomycin. On day 7, bone marrow-derived macrophages were divided into four groups. In the control group, cells were incubated in DMEM/HG containing 10% FBS. In the lipopolysaccharide group, cells were activated with 100 ng/mL lipopolysaccharide (Sigma-Aldrich, St. Louis, MO, USA) and incubated in DMEM/HG containing 10% FBS. In the Con-M and EPC-CM groups, cells were activated with 100 ng/mL lipopolysaccharide and incubated in DMEM/HG containing 10% FBS and either Con-M or EPC-CM (1:1) for 48 hours. Single-cell suspensions were prepared in phosphate-buffered saline (PBS) and blocked with anti-mouse CD16/32 for 10 minutes, and thereafter stained with rat anti-mouse F4/80, CD11b, CD86 or CD206 antibody (1 µg per 1 × 10^6^ cells; BioLegend, CA, USA) for 20 minutes on ice. After three PBS washes, samples were analyzed with the BD FACSverse flow cytometry system (BD, Franklin Lakes, NJ, USA).

Quantitative polymerase chain reaction was used to evaluate mRNA expression levels of inflammatory cytokines. After bone marrow-derived macrophages were activated and incubated for 48 hours, cells were collected. Total RNA was isolated with TRIZOL (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instructions, and then reverse-transcribed into cDNA using the SuperScript II system (Vazyme Biotech, Nanjing, China). GAPDH was used as the internal standard. SYBR Green dye (Vazyme Biotech) was used to monitor amplification. The results are reported as relative quantity values. Relative changes in gene expression levels were analyzed using the 2^−ΔΔCT^ method, as described previously (Schmittgen and Livak, 2008). Gene expression in the control group was normalized to 1, and gene expression in the experimental group was expressed as a ratio to that in the control group (optical density ratio). All assays were performed in triplicate. The primer sequences are shown in [Table 1](#T1){ref-type="table"}.

###### 

Primer sequences

![](NRR-13-887-g002)

### Rat spinal cord neuron culture and apoptosis {#sec3-3}

Rat spinal cord neuron culture and hydrogen peroxide-induced apoptosis were carried out according to a previous report, with modification (Wang et al., 2016). Briefly, single-cell suspensions were collected from rat dissociated spinal cord 24 hours after birth, and then cultured in poly-D-lysine-coated 24-well plates in Neurobasal-A medium supplemented with 2% B27, 0.5 mM glutamine, 100 U/mL penicillin and streptomycin (Gibco, USA) at a density of 600 cells/mm^2^. After 7 days, neurons were divided into four groups. In the control group, cells were incubated in neuronal media. In the H~2~O~2~ group, cells were incubated in neuronal media for 24 hours, and then exposed to 100 μM H~2~O~2~ for 30 minutes. In the Con-M and EPC-CM groups, cells were pretreated with Con-M or EPC-CM for 24 hours, and then exposed to 100 μM H~2~O~2~ for 30 minutes. Cells were stained with propidium iodide (10 μg/mL) and Hoechst 33258 (10 μg/mL) for 15 minutes and fixed with 4% paraformaldehyde for 10 minutes. The cells were observed under a fluorescence microscope (Nikon, Tokyo, Japan). Thirty random fields were manually counted. The proportion of double-stained cells to total cells was calculated.

### Ex vivo aortic ring assay {#sec3-4}

Rat aortic rings were cultured in type I rat tail collagen gel as described by Baker, with modification (Baker et al., 2011). Briefly, 100 μL of the gel was added to each well of a pre-cooled 96-well plate, one aortic ring per well was embedded in the middle of the gel. Aortic rings were cultured in 150 μL EPC-CM or Con-M for 7 days. Photomicrographs were taken under a phase contrast microscope (Nikon, Japan). A minimum of three aortic explants was used per experimental condition, and the experiment was repeated at least three times. Sprout length was calculated digitally using Image J software (National Institutes of Health, Rockville, MD, USA).

*In vivo* experiments {#sec2-3}
---------------------

### Spinal cord injury and treatment {#sec3-5}

A total of 30 adult female Sprague-Dawley rats, weighing 200--250 g, were randomly assigned to the EPC-CM, Con-M and PBS groups (*n* = 10 per group). After intraperitoneal injection of 10% chloral hydrate at a dose of 350 mg/kg and conventional iodine disinfection, complete laminectomy was performed at the T~10~ level, and SCI was induced using a modified Allen's method (10 g from a height of 50 mm). After SCI, the rats exhibited the tail reflex and paralysis of the bilateral hind limbs, indicating successful reproduction of the spinal cord contusive injury model (Allen, 1911). A 1-mL volume of EPC-CM, Con-M or PBS was injected intraperitoneally daily until sacrifice. Rats were housed at 22--25°C and 30--40% humidity under a 12/12-hour light/dark cycle, with free access to food and water. The bladder was manually emptied twice daily until recovery of micturition function.

### Histopathological examination {#sec3-6}

Rats were sacrificed at 1 week (*n* = 5 per group) and 6 weeks (*n* = 5 per group) post-surgery and used for histopathological analyses. After the tissue was fixed in 4% paraformaldehyde and embedded in paraffin, serial 5-μm-thick coronal sections were cut. The sections were stained with rabbit anti-rat CD86 or rabbit anti-rat CD206 (Abcam, MA, USA). Alexa Fluor 594-conjugated goat anti-rabbit and Alexa Fluor 488-conjugated goat anti-rabbit (Life Technologies, NY, USA) secondary antibodies were used. Nuclei were counterstained with 4′,6-diamidino-2-phenylindole. Immunostained sections were observed under a fluorescence microscope (Nikon, Japan).

Immunohistochemistry was used to detect CD31-positive blood vessel lumens 1 week after injury and neurofilament 200 (NF200) density 6 weeks after injury at the lesion site. Rabbit anti-rat CD31 (Abcam) or rabbit anti-rat NF200 (Proteintech, Cambridge, MA, USA) antibody was incubated overnight at 4°C, and then horseradish peroxidase-labeled goat anti-rabbit IgG (Biosynthesis, Beijing, China) was added. Diaminobenzidine and hematoxylin were used as reagent and counterstain. Results were measured with Image J software.

Serial sections made 6 weeks after injury were stained with hematoxylin and eosin, and examined by phase contrast microscopy. Cystic cavities were analyzed according to a previous study (Cantinieaux et al., 2013), and the amount of cavitation was expressed as cavity extent/spinal cord extent × 100%.

### TUNEL assay {#sec3-7}

Apoptosis was assessed 1 week after injury using the TUNEL kit (Roche, Mannheim, Germany), following the manufacturer's instructions. Under a high-power objective (× 200; Nikon), the number of apoptotic cells, characterized by TUNEL-stained nuclei, was counted in four randomly selected fields from four sections for each group.

### Basso, Beattie and Bresnahan (BBB) score {#sec3-8}

The BBB Locomotor Rating Scale (Basso et al., 1995; *n* = 5 per group) was used to assess locomotor function by two independent and blinded observers at 1, 3, 5 and 7 days after surgery, and then every 7 days until sacrifice. The rats were allowed to move freely in an open field apparatus (1 m × 1 m), and their movements were recorded for 5 minutes. Scores were recorded and averaged across both the left and right hind limbs.

### Statistical analysis {#sec3-9}

All data were presented as the mean ± SD and were analyzed with SPSS 17.0 software (SPSS, Chicago, IL, USA). Values were compared using one-way analysis of variance, followed by the least significant difference post hoc analysis for comparisons among multiple groups. *P* values ≤ 0.05 were considered statistically significant.

Results {#sec1-3}
=======

Effect of EPC-CM on macrophage phenotype and inflammatory cytokine release *in vitro* and *in vivo* {#sec2-4}
---------------------------------------------------------------------------------------------------

Flow cytometry showed that EPC-CM significantly reduced expression of the classically activated macrophage (M1) marker CD86 in bone marrow-derived macrophages treated with lipopolysaccharide compared with Con-M, while the alternatively activated macrophage (M2) marker CD206 remained relatively unchanged. These data suggest that ECP-CM suppresses macrophage M1 activation (**Figure** [**1A**](#F1){ref-type="fig"}, [**B**](#F1){ref-type="fig"}).

![Effects of EPC-CM on inflammatory cytokine levels *in vitro* and *in vivo*.\
(A) Representative flow cytometry data showing the effect of EPC-CM on BMDMs. (a) Mature BMDMs were defined as CD11b^+^/F4/80^+^ subpopulations (upper right), with the purity displayed as percentage of the parent population. (b) Control BMDMs were incubated with CD11b and F4/80 antibody and used to set up the gate. (c) Control BMDMs without LPS stimulation were incubated with anti-rat CD11b, F4/80, CD86 and CD206 antibodies. M1 macrophages are CD11b^+^/F4/80^+^/CD86^+^/CD206^−^ (Q1), whereas M2 macrophages are CD11b^+^/F4/80^+^/CD86^−^/CD206^+^ (Q3). (d) BMDMs treated with LPS. (e) BMDMs cultured with Con-M and simultaneously stimulated with LPS. (f) BMDMs cultured with EPC-CM and stimulated with LPS. (B) Quantitation of M1 and M2 cells among the different groups. Compared with the Con-M group, EPC-CM significantly reduced M1 activation, while M2 cells remained relatively unchanged. (C) mRNA expression levels of inflammatory cytokines (optical density ratio) among groups. (D) Immunofluorescence staining for CD86 (M1 marker) and CD206 (M2 marker) in the epicenter 7 days after SCI (*n* = 5 per group; green: CD86; red: CD206; blue: DAPI). (E) Quantification of CD86- and CD206-positive cells at 7 days after SCI. \*\**P* \< 0.01, *vs*. PBS group; \#*P* \< 0.05, \#\#*P* \< 0.01, *vs*. Con-M group. §*P* \< 0.05, §§*P* \< 0.01, *vs*. LPS. Data are presented as the mean ± SD (one-way analysis of variance followed by the least significant difference *post hoc* test). The experiment was performed at least three times. Ctrl: Control; PBS: phosphate-buffered saline; EPC-CM: endothelial progenitor cell--conditioned medium; Con-M: control medium; BMDMs: bone marrow-derived macrophages; LPS: lipopolysaccharide; IL: interleukin; DAPI: 4′,6-diamidino-2-phenylindole.](NRR-13-887-g003){#F1}

We next examined the effect of EPC-CM on the expression of inflammatory cytokines, including IL-1β, IL-6 and IL-10. Quantitative RT-PCR showed that EPC-CM substantially reduced lipopolysaccharide-stimulated expression of the pro-inflammatory cytokines IL-1β and IL-6. In comparison, expression of the anti-inflammatory cytokine IL-10 was not substantially impacted ([**Figure 1C**](#F1){ref-type="fig"}).

To evaluate the immunomodulatory effect of EPC-CM *in vivo*, CD86- and CD206-positive cells in the epicenter were counted 1 week after injury. EPC-CM significantly decreased the number of CD86^+^ cells and markedly increased the number of CD206^+^ cells (**Figure** [**1D**](#F1){ref-type="fig"}--[**E**](#F1){ref-type="fig"}). The *in vitro* and *in vivo* results indicate that EPC-CM exerts a strong anti-inflammatory effect.

EPC-CM suppressed H~2~O~2~-induced neuronal apoptosis *in vitro* and gray matter neuronal apoptosis *in vivo* after SCI {#sec2-5}
-----------------------------------------------------------------------------------------------------------------------

The percentage of propidium iodide and Hoechst 33258 double-stained cells were counted *in vitro*. Apoptotic cells accounted for 51.4 ± 4.1% of total cells in the H~2~O~2~ group, while they accounted for 21.6 ± 3.1% of cells in the Con-M group. EPC-CM significantly attenuated the apoptotic rate to 10.5 ± 1.4% (**Figure** [**2A**](#F2){ref-type="fig"}, [**B**](#F2){ref-type="fig"}). In the gray matter, rats in the EPC-CM group had the fewest TUNEL-positive cells (**Figure** [**2C**](#F2){ref-type="fig"}, [**D**](#F2){ref-type="fig"}). These data demonstrate that EPC-CM attenuates neuronal injury.

![Effect of EPC-CM on apoptosis *in vitro* and *in vivo*.\
(A) *In vitro* representative fluorescence images of Hoechst and PI double staining (original magnification, 200×; blue: Hoechst 33258; red: PI). (B) Quantitative assessment of apoptotic cells in the various groups. EPC-CM significantly reduced H~2~O~2~-induced spinal cord neuron apoptosis. The experiment was performed at least three times. (C) Cells in the gray matter in the epicenter stained with TUNEL one week after injury (*in vivo*). The nuclei of TUNEL-positive (apoptotic) cells are stained a dark color (*n* = 5 per group; original magnification, 200×). (D) Quantitative analysis of TUNEL-positive cells. Compared with the PBS group, the EPC-CM and Con-M groups had significantly fewer TUNEL-positive cells. \*\**P* \< 0.01, *vs*. PBS group; \#*P* \< 0.05, \#\#*P* \< 0.01, *vs*. Con-M group. ††*P* \< 0.01, *vs*. H~2~O~2~ group. Data are presented as the mean ± SD (one-way analysis of variance followed by the least significant difference *post hoc* test). The experiment was performed at least three times. Ctrl: Control; PBS: phosphate-buffered saline; PI: propidium iodide; EPC-CM: endothelial progenitor cell-conditioned msedium; Con-M: control medium; TUNEL: terminal deoxynucleotidyl transferase dUTP nick-end labeling.](NRR-13-887-g004){#F2}

Effect of EPC-CM on angiogenesis *in vitro* and *in vivo* {#sec2-6}
---------------------------------------------------------

To examine the pro-angiogenic effect of EPC-CM *in vitro*, we performed the aortic ring assay. EPC-CM had a substantially more robust angiogenic effect, compared with Con-M, evidenced as a significantly wider and clearly denser network of vascular sprouts emerging from the aorta (**Figure** [**3A**](#F3){ref-type="fig"}, [**B**](#F3){ref-type="fig"}). Furthermore, the EPC-CM group showed the highest number of CD31-positive vascular lumens in the epicenter 7 days after SCI (**Figure** [**3C**](#F3){ref-type="fig"}, [**D**](#F3){ref-type="fig"}). These results show that EPC-CM promotes angiogenesis.

![Effects of EPC-CM on angiogenesis in rats *in vitro* and *in vivo*.\
(A) *In vitro* representative photomicrographs of vessel outgrowth from 1-mm rat aortic rings embedded in type I rat tail collagen gel and incubated with EPC-CM or Con-M. EPC-CM-treated aortic ring shows a wider and denser network of vascular sprouts (original magnification, 40×). Scale bars: 25 μm. (B) Quantitative analysis of sprout length induced by incubation with Con-M or EPC-CM. (C) Representative images of immunostained sections showing CD31-positive lumens in the epicenter in the various groups (*in vivo*). The typical positive lumens contain a blue nucleus and a brown endothelium. Scale bars: 100 μm. (D) Assessment of the number of CD31^+^ lumens. \**P* \< 0.05, \*\**P* \< 0.01, *vs*. PBS group; \#*P* \< 0.05, \#\#*P* \< 0.01, *vs*. Con-M group. Data are presented as the mean ± SD (one-way analysis of variance followed by the least significant difference *post hoc* test). The experiment was performed at least three times. PBS: Phosphate-buffered saline; EPC-CM: endothelial progenitor cell-conditioned medium; Con-M: control medium.](NRR-13-887-g005){#F3}

EPC-CM enhanced axonal regeneration, reduced cystic cavities, and promoted functional recovery {#sec2-7}
----------------------------------------------------------------------------------------------

To assess the impact of EPC-CM on axonal regrowth, NF200 immunostaining was performed. NF200-positive axonal density was markedly increased in the EPC-CM group compared with the Con-M and PBS groups. Furthermore, the EPC-CM group showed dramatically reduced mean size of cystic cavities compared with the other groups (**Figure** [**4A**](#F4){ref-type="fig"}, [**B**](#F4){ref-type="fig"}). From day 7 onwards after SCI, EPC-CM-treated animals exhibited better scores than Con-M-treated animals, and this difference was sustained ([**Figure 5**](#F5){ref-type="fig"}).

![Effects of EPC-CM on the histomorphology of the injured rat spinal cord.\
(A) Representative images of NF200 immunostaining in the gray matter at the lesion site (upper panel, scale bar: 100 μm; nuclei are stained blue, and positive cells are stained brown) and cavities by HE staining (lower panel, original magnification, 40×; nuclei are stained blue, and the cytoplasm is stained pink). (B) Quantitation of NF200-positive density and areas of cystic cavities (cavity extent/spinal cord extent × 100%) in the various groups. \**P* \< 0.05, \*\**P* \< 0.01, *vs*. PBS group; \#*P* \< 0.05, \#\#*P* \< 0.01, *vs*. Con-M group. Data are presented as the mean ± SD (one-way analysis of variance followed by the least significant difference *post hoc* test). The experiment was performed at least three times. PBS: Phosphate-buffered saline; EPC-CM: endothelial progenitor cell-conditioned medium; Con-M: control medium; HE: hematoxylin-eosin; NF200: neurofilament 200.](NRR-13-887-g006){#F4}

![Effects of EPC-CM on motor functional recovery in rats at various time points after spinal cord injury.\
The BBB score was evaluated every week after injury (*n* = 5 per group). There were significant differences among the three groups after surgery from day 7 onwards. \#*P* \< 0.05, \#\#*P* \< 0.01, *vs*. Con-M group; \*\**P* \< 0.01, *vs*. PBS group. Data are presented as the mean ± SD (one-way analysis of variance followed by the least significant difference *post hoc* test). The experiment was performed at least three times. PBS: Phosphate-buffered saline; EPC-CM: endothelial progenitor cell--conditioned medium; Con-M: control medium; BBB: Basso, Beattie and Bresnahan.](NRR-13-887-g007){#F5}

Discussion {#sec1-4}
==========

In the present study, we found the following: (1) EPC-CM exerts anti-inflammatory effects by reducing M1 macrophage activation and pro-inflammatory cytokine release; (2) EPC-CM promotes angiogenesis *in vitro* and *in vivo*; and (3) EPC-CM reduces neuronal apoptosis to provide neuroprotection. Together, these effects of EPC-CM result in tissue sparing and locomotor functional recovery after contusive SCI in the rat.

EPCs release a variety of factors, such as vascular endothelial growth factor, brain-derived neurotrophic factor and hepatocyte growth factor, which inhibit inflammation (Pías-Peleteiro et al., 2017). Wang et al. (2015) reported that vascular endothelial growth factor 165 decreases the levels of IL-1β, IL-10 and tumor necrosis factor-α in the culture medium of lipopolysaccharide-treated spinal neuron--glia co-cultures. Ji et al. (2015) showed that local injection of a lentiviral vector expressing brain-derived neurotrophic factor at the lesion site promotes a shift from the M1 to the M2 phenotype and reduces the inflammatory response after SCI. Hepatocyte growth factor is a potent anti-inflammatory factor that alleviates inflammation and dysfunction in a wide variety of experimental animal models, such as rheumatoid arthritis and autoimmune neuroinflammation (Molnarfi et al., 2015). A previous study provided evidence that EPC transplantation suppresses the expression of pro-inflammatory cytokines, such as tumor necrosis factor-α and IL-6, after SCI (Fujioka et al., 2012). Our present study shows that EPC-CM decreases M1 activation and suppresses mRNA expression of pro-inflammatory cytokines in bone marrow-derived macrophages. The *in vivo* findings show that CD86^+^ macrophages are downregulated, while CD206^+^ macrophages are upregulated. We suspect that the difference between our *in vitro* and *in vivo* results might be attributed to differences in the animals used. However, both the *in vitro* and *in vivo* findings show that EPC-CM reduces the number of pro-inflammatory macrophages, strongly suggesting, for the first time, that EPC-CM exerts an anti-inflammatory effect. Our results are partially in accordance with those of Cheng et al. (2017) but inconsistent with those of Cantinieaux et al. (2013). In the study by Cheng and colleagues, neural stem cell-conditioned medium significantly downregulated M1 macrophages, while M2 macrophages remained relatively unchanged. Furthermore, IL-10 expression was maintained *in vitro*, but substantially reduced *in vivo*. Cantinieaux et al. (2013) reported that bone marrow-derived mesenchymal stem cell-conditioned medium favors a pro-inflammatory state, as indicated by the significant increase in IL-1β secretion and the apparent, but non-significant, increase in IL-6 and tumor necrosis factor-α production. These discrepancies could possibly be ascribed to differences in the conditioned media and model species used.

It is generally thought that increasing angiogenesis and restoring normal vascular perfusion soon after injury is crucial for repair of the spinal cord (Graumann et al., 2011). Angiogenesis is indeed known to induce tissue protection via increased blood flow by supplying many nutritional substances and oxygen that help protect injured spinal tissue from further degradation. Previous studies showed that transplantation of CD133^+^ cells markedly increases the diameter and number of blood vessels in the epicenter of the injury site (Fujioka et al., 2012; Kamei et al., 2013). Our current findings suggest that EPC-CM enhances angiogenesis at the site of SCI. It is not known which factor in EPC-CM stimulates angiogenesis; however, we speculate that vascular endothelial growth factor plays a major role. Vascular endothelial growth factor is a key mediator of angiogenesis during spinal cord development and SCI (Chung and Ferrara, 2011). Several studies show that vascular endothelial growth factor promotes angiogenesis in central and peripheral regions when delivered directly or *via* gene therapy (Widenfalk et al., 2003; Yun et al., 2017). For example, exogenous vascular endothelial growth factor 165 delivered locally immediately after SCI increases blood vessel density in the rat.

Neuronal death rapidly followed by oligodendrocyte apoptosis is characteristic of secondary injury in SCI. Here, we found that EPC-CM protects neurons from apoptosis *in vitro* and *in vivo*. EPCs cultured under 1.5% oxygen secrete factors related to neuroprotection, such as vascular endothelial growth factor, brain-derived neurotrophic factor and hepatocyte growth factor (Di Santo et al., 2009). Vascular endothelial growth factor reduces apoptosis at the epicenter of injury, as well as 1, 2 and 3 mm distally, as assessed by TUNEL staining (Liu et al., 2010). In addition, vascular endothelial growth factor is a potential neurotrophic factor, promoting neuronal survival in cells cultured in oxygen- and glucose-deprived conditions (Jin et al., 2000). Brain-derived neurotrophic factor rescues neurons after SCI *via* the TrkB/PI3-kinase/Akt pathway (Weishaupt et al., 2012). Furthermore, hepatocyte growth factor exerts neuroprotective effects after SCI *via* the hepatocyte growth factor receptor (Met) pathway (Kitamura et al., 2011). A recent study showed that the cytoprotective effects of human EPC-CM against ischemic insult are not vascular endothelial growth factor or IL-8-dependent (Di Santo et al., 2016). The key factors mediating the neuroprotective effects of EPC-CM are unclear and need further investigation.

Here, we observed that EPC-CM significantly promoted axonal regeneration, as evidenced by an increase in NF200 immunoreactivity in the gray matter, and it reduced cystic cavity volume. Importantly, EPC-CM improved BBB scores, suggesting that it promotes functional recovery after SCI.

In summary, the systemic delivery of EPC-CM alleviates inflammation, promotes angiogenesis and provides neuroprotection to improve axonal regeneration and functional recovery after SCI. This novel cell-free therapy circumvents the concerns and restrictions of cell transplantation. However, further studies are needed to identify the factors and signaling pathways underlying the effectiveness of EPC-CM. Nonetheless, EPC-CM may have therapeutic potential for the treatment of SCI.
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